Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.44 |
| ▸ | TTK | P33981 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22658448 | 1.00 | LRRK2 (0.57) | LRRK2KMT2APTK2TTKALDH1A1 | |
| SCHEMBL24556827 | 1.00 | LRRK2 (0.57) | LRRK2KMT2APTK2TTKALDH1A1 | |
| SCHEMBL29409884 | 1.00 | LRRK2 (0.57) | LRRK2KMT2APTK2TTKALDH1A1 | |
| SCHEMBL29409860 | 1.00 | LRRK2 (0.57) | LRRK2KMT2APTK2TTKALDH1A1 | |
| SCHEMBL24556814 | 0.94 | LRRK2 (0.53) | LRRK2KMT2APTK2TTKZAP70 | |
| SCHEMBL24556858 | 0.94 | LRRK2 (0.53) | LRRK2KMT2APTK2TTKZAP70 | |
| SCHEMBL29409886 | 0.94 | LRRK2 (0.53) | LRRK2KMT2APTK2TTKZAP70 | |
| SCHEMBL29409850 | 0.94 | LRRK2 (0.53) | LRRK2KMT2APTK2TTKZAP70 | |
| SCHEMBL24059629 | 0.90 | LRRK2 (0.60) | LRRK2KMT2APTK2 | |
| SCHEMBL25107242 | 0.90 | TTK (0.53) | LRRK2KMT2APTK2TTKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479847-B2 | Pyrrolopyrimidine inhibitors of wild-type and mutant forms of LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20220204515-A1 | PYRROLOPYRIMIDINE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| WO-2020232332-A1 | PYRROLOPYRIMIDINE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204515-A1 | PYRROLOPYRIMIDINE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | LRRK2, PARK7, PINK1 | LRRK2 1/4885KMT2A 1326/4885PTK2 533/4885 |
| US-12479847-B2 | Pyrrolopyrimidine inhibitors of wild-type and mutant forms of LRRK2 | LRRK2, PARK7, PINK1 | LRRK2 1/4885KMT2A 1326/4885PTK2 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.